426 related articles for article (PubMed ID: 32485484)
1. Combinatorial Pharmacogenomic Algorithm is Predictive of Citalopram and Escitalopram Metabolism in Patients with Major Depressive Disorder.
Shelton RC; Parikh SV; Law RA; Rothschild AJ; Thase ME; Dunlop BW; DeBattista C; Conway CR; Forester BP; Macaluso M; Hain DT; Aguilar AL; Brown K; Lewis DJ; Jablonski MR; Greden JF
Psychiatry Res; 2020 Aug; 290():113017. PubMed ID: 32485484
[TBL] [Abstract][Full Text] [Related]
2. CYP2C19 genotype predicts steady state escitalopram concentration in GENDEP.
Huezo-Diaz P; Perroud N; Spencer EP; Smith R; Sim S; Virding S; Uher R; Gunasinghe C; Gray J; Campbell D; Hauser J; Maier W; Marusic A; Rietschel M; Perez J; Giovannini C; Mors O; Mendlewicz J; McGuffin P; Farmer AE; Ingelman-Sundberg M; Craig IW; Aitchison KJ
J Psychopharmacol; 2012 Mar; 26(3):398-407. PubMed ID: 21926427
[TBL] [Abstract][Full Text] [Related]
3. Combinatorial pharmacogenomic algorithm is predictive of sertraline metabolism in patients with major depressive disorder.
Parikh SV; Law RA; Hain DT; Rothschild AJ; Thase ME; Dunlop BW; DeBattista C; Forester BP; Shelton RC; Macaluso M; Cogan ES; Brown K; Lewis DJ; Jablonski MR; Greden JF
Psychiatry Res; 2022 Feb; 308():114354. PubMed ID: 34986431
[TBL] [Abstract][Full Text] [Related]
4. Clinical validation of combinatorial pharmacogenomic testing and single-gene guidelines in predicting psychotropic medication blood levels and clinical outcomes in patients with depression.
Rothschild AJ; Parikh SV; Hain D; Law R; Thase ME; Dunlop BW; DeBattista C; Conway CR; Forester BP; Shelton RC; Macaluso M; Brown K; Lewis D; Gutin A; Jablonski MR; Greden JF
Psychiatry Res; 2021 Feb; 296():113649. PubMed ID: 33360967
[TBL] [Abstract][Full Text] [Related]
5. Citalopram and escitalopram plasma drug and metabolite concentrations: genome-wide associations.
Ji Y; Schaid DJ; Desta Z; Kubo M; Batzler AJ; Snyder K; Mushiroda T; Kamatani N; Ogburn E; Hall-Flavin D; Flockhart D; Nakamura Y; Mrazek DA; Weinshilboum RM
Br J Clin Pharmacol; 2014 Aug; 78(2):373-83. PubMed ID: 24528284
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic-Pharmacodynamic interaction associated with venlafaxine-XR remission in patients with major depressive disorder with history of citalopram / escitalopram treatment failure.
Ahmed AT; Biernacka JM; Jenkins G; Rush AJ; Shinozaki G; Veldic M; Kung S; Bobo WV; Hall-Flavin DK; Weinshilboum RM; Wang L; Frye MA
J Affect Disord; 2019 Mar; 246():62-68. PubMed ID: 30578947
[TBL] [Abstract][Full Text] [Related]
7. CYP2C19-Guided Escitalopram and Sertraline Dosing in Pediatric Patients: A Pharmacokinetic Modeling Study.
Strawn JR; Poweleit EA; Ramsey LB
J Child Adolesc Psychopharmacol; 2019 Jun; 29(5):340-347. PubMed ID: 30817183
[No Abstract] [Full Text] [Related]
8. Escitalopram in Adolescents With Generalized Anxiety Disorder: A Double-Blind, Randomized, Placebo-Controlled Study.
Strawn JR; Mills JA; Schroeder H; Mossman SA; Varney ST; Ramsey LB; Poweleit EA; Desta Z; Cecil K; DelBello MP
J Clin Psychiatry; 2020 Aug; 81(5):. PubMed ID: 32857933
[TBL] [Abstract][Full Text] [Related]
9. Clinical validity: Combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes.
Altar CA; Carhart JM; Allen JD; Hall-Flavin DK; Dechairo BM; Winner JG
Pharmacogenomics J; 2015 Oct; 15(5):443-51. PubMed ID: 25686762
[TBL] [Abstract][Full Text] [Related]
10. Impact of age on serum concentrations of venlafaxine and escitalopram in different CYP2D6 and CYP2C19 genotype subgroups.
Waade RB; Hermann M; Moe HL; Molden E
Eur J Clin Pharmacol; 2014 Aug; 70(8):933-40. PubMed ID: 24858822
[TBL] [Abstract][Full Text] [Related]
11. Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response.
Tsai MH; Lin KM; Hsiao MC; Shen WW; Lu ML; Tang HS; Fang CK; Wu CS; Lu SC; Liu SC; Chen CY; Liu YL
Pharmacogenomics; 2010 Apr; 11(4):537-46. PubMed ID: 20350136
[TBL] [Abstract][Full Text] [Related]
12. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants.
Bousman CA; Stevenson JM; Ramsey LB; Sangkuhl K; Hicks JK; Strawn JR; Singh AB; Ruaño G; Mueller DJ; Tsermpini EE; Brown JT; Bell GC; Leeder JS; Gaedigk A; Scott SA; Klein TE; Caudle KE; Bishop JR
Clin Pharmacol Ther; 2023 Jul; 114(1):51-68. PubMed ID: 37032427
[TBL] [Abstract][Full Text] [Related]
13. Influence of
Islam F; Magarbeh L; Elsheikh SSM; Kloiber S; Espinola CW; Bhat V; Frey BN; Milev R; Soares CN; Parikh SV; Placenza F; Hassel S; Taylor VH; Leri F; Blier P; Uher R; Farzan F; Lam RW; Turecki G; Foster JA; Rotzinger S; Kennedy SH; Müller DJ
Can J Psychiatry; 2024 Mar; 69(3):183-195. PubMed ID: 37796764
[TBL] [Abstract][Full Text] [Related]
14. Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting.
Hall-Flavin DK; Winner JG; Allen JD; Carhart JM; Proctor B; Snyder KA; Drews MS; Eisterhold LL; Geske J; Mrazek DA
Pharmacogenet Genomics; 2013 Oct; 23(10):535-48. PubMed ID: 24018772
[TBL] [Abstract][Full Text] [Related]
15. A Call for Clear and Consistent Communications Regarding the Role of Pharmacogenetics in Antidepressant Pharmacotherapy.
Hicks JK; Bishop JR; Gammal RS; Sangkuhl K; Bousman CA; Leeder JS; Llerena A; Mueller DJ; Ramsey LB; Scott SA; Skaar TC; Caudle KE; Klein TE; Gaedigk A
Clin Pharmacol Ther; 2020 Jan; 107(1):50-52. PubMed ID: 31664715
[No Abstract] [Full Text] [Related]
16. Dual Roles for the TSPYL Family in Mediating Serotonin Transport and the Metabolism of Selective Serotonin Reuptake Inhibitors in Patients with Major Depressive Disorder.
Qin S; Eugene AR; Liu D; Zhang L; Neavin D; Biernacka JM; Yu J; Weinshilboum RM; Wang L
Clin Pharmacol Ther; 2020 Mar; 107(3):662-670. PubMed ID: 31628858
[TBL] [Abstract][Full Text] [Related]
17. Impact of cytochrome P450 2C19 polymorphisms on citalopram/escitalopram exposure: a systematic review and meta-analysis.
Chang M; Tybring G; Dahl ML; Lindh JD
Clin Pharmacokinet; 2014 Sep; 53(9):801-11. PubMed ID: 25154506
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetic Factors Influence Escitalopram Pharmacokinetics and Adverse Events in Youth with a Family History of Bipolar Disorder: A Preliminary Study.
Honeycutt DC; Blom TJ; Ramsey LB; Strawn JR; Bruns KM; Welge JA; Patino LR; Singh MK; DelBello MP
J Child Adolesc Psychopharmacol; 2024 Feb; 34(1):42-51. PubMed ID: 38377518
[No Abstract] [Full Text] [Related]
19. Escitalopram.
Burke WJ
Expert Opin Investig Drugs; 2002 Oct; 11(10):1477-86. PubMed ID: 12387707
[TBL] [Abstract][Full Text] [Related]
20. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors.
Hicks JK; Bishop JR; Sangkuhl K; Müller DJ; Ji Y; Leckband SG; Leeder JS; Graham RL; Chiulli DL; LLerena A; Skaar TC; Scott SA; Stingl JC; Klein TE; Caudle KE; Gaedigk A;
Clin Pharmacol Ther; 2015 Aug; 98(2):127-34. PubMed ID: 25974703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]